Fluconazole loading dose pharmacokinetics and safety in infants

Pediatric Infectious Disease Journal

Volumn 30, Issue 5, 2011, Pages 375-378

  Piper, Lauren ^a   Smith, P Brian ^a   Hornik, Christoph P ^a   Cheifetz, Ira M ^a   Barrett, Jeffrey S ^b   Moorthy, Ganesh ^b   Hope, William W ^c   Wade, Kelly C ^b   Cohen Wolkowiez Jr , Michael ^a   Benjamin, Daniel K ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

candidiasis; fluconazole; infant; neonate; pharmacology

Indexed keywords

FLUCONAZOLE;

ABSENCE OF SIDE EFFECTS; ARTICLE; CLINICAL ARTICLE; DOSE RESPONSE; DRUG SAFETY; HOSPITAL PATIENT; HUMAN; INFANT; LOADING DRUG DOSE; NEWBORN; PRIORITY JOURNAL; STEADY STATE; SYSTEMIC MYCOSIS; TREATMENT OUTCOME;

EID: 79954720422     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318202cbb3     Document Type: Article

References (31)

1. Benjamin DK Jr, Poole C, Steinbach WJ, et al. Neonatal candidemia and end-organ damage: a critical appraisal ofthe literature using meta-analytic techniques. Pediatrics. 2003;112:634-640. (Pubitemid 37082118)
2. Garey KW, Rege M, Pai MP, et al. Time to initiation offluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis. 2006;43:25-31. (Pubitemid 43939072)
3. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005;49:3640-3645. (Pubitemid 41233011)
4. Benjamin DK Jr, Stoll BJ. Infection in late preterm infants. Clin Perinatol. 2006;33:871-882. (Pubitemid 44828736)
5. Stoll BJ, Hansen N, Fanaroff AA, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Net-work. Pediatrics. 2002;110:285-291. (Pubitemid 34833012)
6. Steinbach WJ, Walsh TJ. Mycoses in pediatric patients. Infect Dis Clin North Am. 2006;20:663-678. (Pubitemid 44389928)
7. Diflucan [package insert]. New York: Roerig, a division of Pfizer, Inc.; 2008.
8. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment ofcandidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med. 1994;331:1325-1330. (Pubitemid 24347001)
9. Malik IA, Moid I, Aziz Z, et al. A randomized comparison offluconazole with amphotericin B as empiric anti-fungal agents in cancer patients with prolonged fever and neutropenia. Am J Med. 1998;105:478-483. (Pubitemid 29013332)
10. Winston DJ, Hathorn JW, Schuster MG, et al. A multicenter, randomized trial offluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med. 2000;108:282-289. (Pubitemid 30110456)
11. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment ofcandidiasis. Clin Infect Dis. 2004;38:161-189.
12. Clancy CJ, Staley B, Nguyen MH. In vitro susceptibility ofbreakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole. Antimicrob Agents Chemother. 2006;50:3496-3498. (Pubitemid 44527536)
13. Clancy CJ, Yu VL, Morris AJ, et al. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob Agents Chemother. 2005;49:3171-3177. (Pubitemid 41060556)
14. Wade KC, Benjamin DK Jr, Kaufman DA, et al. Fluconazole dosing for the prevention or treatment of invasive candidiasis in young infants. Pediatr Infect Dis J. 2009;28:717-723.
15. Wade KC, Wu D, Kaufman DA, et al. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother. 2008;52: 4043-4049.
16. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin Infect Dis. 2000; 30:662-678.
17. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503-535.
18. Wu D, Wade KC, Paul DJ, et al. A rapid and sensitive LC-MS/MS method for determination of fluconazole in human plasma and its application in infants with Candida infections. Ther Drug Monit. 2009;31:703-709.
19. Flückiger U, Marchetti O, Bille J, et al. Treatment options of invasive fungal infections in adults. Swiss Med Wkly. 2006;136:447-463. (Pubitemid 44220568)
20. Nolla-Salas J, Sitges-Serra A, León-Gil C, et al. Candidemia in non-neutropenic critically ill patients: analysis ofprognostic factors and assess-ment ofsystemic antifungal therapy. Study Group ofFungal Infection in the ICU. Intensive Care Med. 1997;23:23-30. (Pubitemid 27067892)
21. Olaechea PM, Palomar M, León-Gil C, et al. Economic impact ofCandida colonization and Candida infection in the critically ill patient. Eur J Clin Microbiol Infect Dis. 2004;23:323-330. (Pubitemid 38669943)
22. Eggimann P, Francioli P, Bille J, et al. Fluconazole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. Crit Care Med. 1999;27:1066-1072. (Pubitemid 29314312)
23. Pelz RK, Hendrix CW, Swoboda SM, et al. Double-blind placebo-con-trolled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg. 2001;233:542-548. (Pubitemid 32234953)
24. Andes D, van Ogtrop M. Characterization and quantitation ofthe pharma-codynamics of fluconazole in a neutropenic murine disseminated candidi-asis infection model. Antimicrob Agents Chemother. 1999;43:2116-2120. (Pubitemid 29421186)
25. Buck ML. Pharmacokinetic changes during extracorporeal membrane ox-ygenation: implications for drug therapy ofneonates. Clin Pharmacokinet. 2003;42:403-417. (Pubitemid 36649036)
26. Southgate WM, DiPiro JT, Robertson AF. Pharmacokinetics ofgentamicin in neonates on extracorporeal membrane oxygenation. Antimicrob Agents Chemother. 1989;33:817-819. (Pubitemid 19146566)
27. Hoie EB, Swigart SA, Leuschen MP, et al. Vancomycin pharmacokinetics in infants undergoing extracorporeal membrane oxygenation. Clin Pharm. 1990;9:711-715. (Pubitemid 20323745)
28. Amaker RD, DiPiro JT, Bhatia J. Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation. Antimicrob Agents Chemother. 1996;40:1139-1142. (Pubitemid 26136023)
29. Buck ML. Vancomycin pharmacokinetics in neonates receiving extracor-poreal membrane oxygenation. Pharmacotherapy. 1998;18:1082-1086. (Pubitemid 28439994)
30. Paden ML, Warshaw BL, Heard ML, et al. Recovery of renal function and survival after continuous renal replacement therapy during extracorporeal membrane oxygenation. Pediatr Crit Care Med. 2010 May 6 [Epub ahead ofprint].
31. Novelli V, Holzel H. Safety and tolerability offluconazole in children Antimicrob Agents Chemother. 1999;43:1955-1960